散发性阿尔茨海默病中与父母症状发作年龄的接近程度及β淀粉样蛋白负荷
这项队列研究分析了PREVENT-AD队列101名认知正常个体的脑脊液Aβ1-42,并按与父母症状发作年龄的接近程度评估其与Aβ水平的关系,在ACS和WRAP两个独立队列中重复分析。结果显示,在PREVENT-AD队列中,接近父母发病年龄的个体脑脊液Aβ1-42水平较低(B=-9.09,P=.04),该关联在APOE4携带者(B=-17.9,P=.03)和女性(B=-19.8,P=.02)中更强;ACS队列用PIB-PET数据重复了主要关联,WRAP队列的横断面数据未重复出结果,但纵向PIB-PET数据重复了主要关联和APOE交互作用。
要点
- 在PREVENT-AD队列中,接近父母发病年龄与较低的脑脊液Aβ1-42水平相关(B=-9.09,P=.04)。
- 该关联在APOE4携带者(B=-17.9,P=.03)和女性(B=-19.8,P=.02)中更强。
- ACS队列用PIB-PET重复了主要关联,WRAP队列横断面数据未重复出结果。
核心结论
- 结果提示,对于有散发性阿尔茨海默病家族史的无症状个体,与父母症状发作年龄的接近程度可能有助于估计女性或APOE4携带者的Aβ生物标志物变化。
研究设计与样本
- 这项队列研究分析了PREVENT-AD队列中101名认知正常个体的脑脊液Aβ1-42,该队列在2011年9月1日至2016年11月30日期间共入组374名参与者。
- 研究通过将参与者当前年龄减去其受累亲属的发病年龄来估计与父母症状发作的接近程度。
- 分析中使用载脂蛋白E ε4(APOE4)状态和性别作为交互项,并在ACS和WRAP两个独立队列中使用脑脊液和PIB-PET Aβ生物标志物重复分析。
主要发现
- PREVENT-AD队列纳入101人(平均[SD]年龄61.8[5.1]岁;30[29.7%]男性),ACS队列纳入128人(112人接受脑脊液检测:平均[SD]年龄63.4[5.1]岁,31[27.7%]男性;107人接受PIB-PET:平均[SD]年龄64.6[5.3]岁,27[25.2%]男性),WRAP队列纳入135人(85人接受脑脊液检测:平均[SD]年龄59.9[6.0]岁,27[31.8%]男性;135人接受PIB-PET:平均[SD]年龄59.6[6.1]岁,43[31.9%]男性)。
- 在PREVENT-AD队列中,接近父母发病年龄的个体脑脊液Aβ1-42水平较低(范围402-1597;B=-9.09,P=.04)。
- 该关联在APOE4携带者中更强(B=-17.9,P=.03),在女性中也更强(B=-19.8,P=.02)。
- 在ACS队列中,使用PIB-PET数据重复了主要关联,并使用脑脊液和PIB-PET数据重复了性别交互作用。
- 在WRAP队列中,横断面数据未重复出结果,但纵向PIB-PET数据重复了主要关联和APOE交互作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Alzheimer disease (AD) develops during several decades. Presymptomatic individuals might be the best candidates for clinical trials, but their identification is challenging because they have no symptoms. OBJECTIVE: To assess whether a sporadic parental estimated years to symptom onset calculation could be used to identify information about amyloid-β (Aβ) levels in asymptomatic individuals with a parental history of AD dementia. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed Aβ1-42 in cerebrospinal fluid (CSF) specimens from 101 cognitively normal individuals who had a lumbar puncture as part of the Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) cohort from September 1, 2011, through November 30, 2016 (374 participants were enrolled in the cohort during this period). The study estimated each participant's proximity to his/her parent's symptom onset by subtracting the index relative's onset age from his/her current age. The association between proximity to parental symptom onset and Aβ levels was then assessed using apolipoprotein E ε4 (APOE4) status and sex as interactive terms. These analyses were performed again in 2 independent cohorts using CSF and Pittsburgh compound B carbon 11-labeled positron emission tomography (PIB-PET) Aβ biomarkers: the Adult Children Study (ACS) and the Wisconsin Registry for Alzheimer Prevention (WRAP) cohorts. MAIN OUTCOMES AND MEASURES: The association between proximity to parental symptom onset and Aβ burden in asymptomatic individuals with a parental history of sporadic AD. RESULTS: The present analysis included a subset of 101 PREVENT-AD individuals (mean [SD] age, 61.8 [5.1] years; 30 [29.7%] male), 128 ACS participants (112 participants underwent CSF measurement: mean [SD] age, 63.4 [5.1] years; 31 [27.7%] male; and 107 underwent PIB-PET: mean [SD] age, 64.6 [5.3] years; 27 [25.2%] male), and 135 WRAP participants (85 participants underwent CSF measurement: mean [SD] age, 59.9 [6.0] years; 27 [31.8%] male; and 135 underwent PIB-PET: mean [SD] age, 59.6 [6.1] years; 43 [31.9%] male). In the PREVENT-AD cohort, individuals approaching their parent's onset age had lower CSF Aβ1-42 levels (range, 402-1597; B = -9.09, P = .04). This association was stronger in APOE4 carriers (B = -17.9, P = .03) and women (B = -19.8, P = .02). In the ACS cohort, the main association was replicated using PIB-PET data, and the sex interaction was replicated using CSF and PIB-PET data. In the WRAP cohort, the results were not replicated using cross-sectional data, but the main association and the APOE interaction were replicated using PIB-PET longitudinal data. CONCLUSIONS AND RELEVANCE: These results suggest that proximity to parental symptom onset may help estimate Aβ biomarker changes in women or APOE4 carrier asymptomatic individuals with a parental history of sporadic AD.
引用
- Villeneuve S, Vogel JW, Gonneaud J, et al. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease. JAMA Neurol. 2018. PMID: 29482212. doi:10.1001/jamaneurol.2017.5135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。